Maximizing the treatment of overactive bladder with sacral nerve stimulation

MacDiarmid, Scott

doi:10.1002/9781118640562.ch14

Cited by 24 publications

(33 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 OAB is a chronic condition, the prevalence of which increases with age, and it can have a substantial impact on quality of life. 2,3 OAB is thought to affect more than 400 million people worldwide and it has been estimated that 12.4% of the population in Japan experience the symptoms of OAB. 4,5 Antimuscarinic agents are the most commonly prescribed therapeutic agents for the treatment of OAB, but bothersome side-effects, such as dry mouth and constipation, can result in low patient adherence.…”

Section: Introductionmentioning

confidence: 99%

Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real‐World Clinical Setting: A Japanese Post‐Marketing Study

Nozawa

Kato

Tabuchi

et al. 2016

LUTS

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real‐World Clinical Setting: A Japanese Post‐Marketing Study

Nozawa

Kato

Tabuchi

et al. 2016

LUTS

View full text Add to dashboard Cite

show abstract

“…Lower urinary tract symptoms, including those associated with OAB, are prevalent in approximately half of the general population (3), are often debilitating and have a significant impact on patients' daily routines and quality of life (3)(4)(5). OAB affects 12-16% of the adult population across Europe, the USA and Japan (6)(7)(8), and its prevalence increases with age, affecting approximately 30% of individuals > 65 years of age (9), therefore representing a substantive health problem for the ageing population.…”

Section: Introductionmentioning

confidence: 99%

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double‐blind, placebo‐controlled, phase III studies

et al. 2013

View full text Add to dashboard Cite

IntroductionTo examine pooled efficacy data from three, large phase III studies comparing mirabegron (50 and 100 mg) with placebo, and pooled safety data including additional mirabegron 25 mg and tolterodine extended release (ER) 4 mg results.MethodsThis prespecified pooled analysis of three randomised, double-blind, placebo-controlled, 12-week studies, evaluated efficacy and safety of once-daily mirabegron 25 mg (safety analysis), 50 or 100 mg (efficacy and safety analyses) and tolterodine ER 4 mg (safety analysis) for the treatment of symptoms of overactive bladder (OAB). Co-primary efficacy measures were change from baseline to Final Visit in the mean number of incontinence episodes/24 h and mean number of micturitions/24 h. Key secondary efficacy end-points included mean number of urgency episodes/24 h and mean volume voided/micturitions, while other end-points included patient-reported outcomes according to the Treatment Satisfaction-Visual Analogue Scale (TS-VAS) and responder analyses [dry rate (posttreatment), ≥ 50% reduction in incontinence episodes/24 h, ≤ 8 micturitions/24 h (post hoc analysis)]. The safety analysis included adverse event (AE) reporting, laboratory assessments, ECG, postvoid residual volume and vital signs (blood pressure, pulse rate).ResultsMirabegron (50 and 100 mg once daily) demonstrated statistically significant improvements compared with placebo for the co-primary end-points, key secondary efficacy variables, TS-VAS and responder analyses (all comparisons p < 0.05). Mirabegron is well tolerated and demonstrates a good safety profile. The most common AEs (≥ 3%) included hypertension, nasopharyngitis and urinary tract infection (UTI); the incidence of hypertensive events and UTIs decreased with increasing dose. For mirabegron, the incidence of the bothersome antimuscarinic AE, dry mouth, was at placebo level and of a lesser magnitude than tolterodine.ConclusionThe efficacy and safety of mirabegron are demonstrated in this large pooled clinical trial dataset in patients with OAB.

show abstract

“…1 OAB is a chronic condition thought to affect over 400 million people worldwide and its prevalence increases with age. [2][3][4] In Japan, it is estimated that 12.5% of the population over the age of 40 years experience the symptoms of OAB. 5 Antimuscarinic agents are the most commonly prescribed therapeutic agents for treatment of OAB, but bothersome side-effects, such as dry-mouth and constipation, result in low patient adherence.…”

Section: Introductionmentioning

confidence: 99%

Real‐world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post‐marketing study

et al. 2016

View full text Add to dashboard Cite

show abstract

Maximizing the treatment of overactive bladder with sacral nerve stimulation

Cited by 24 publications

References 24 publications

Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real‐World Clinical Setting: A Japanese Post‐Marketing Study

Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real‐World Clinical Setting: A Japanese Post‐Marketing Study

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double‐blind, placebo‐controlled, phase III studies

Real‐world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post‐marketing study

Contact Info

Product

Resources

About